Teva Pharmaceutical reported preliminary data from two studies, Coptimize and QualiCop.
The global Coptimize study, which followed 688 patients from 19 countries, demonstrated that patients who switched to Copaxone from other approved disease modifying therapies experienced a significant reduction of 61% in ARR.
Switching to Copaxone treatment also halted the progression of disability of patients in the trial. A majority of patients reported better overall well being and less adverse events after switching to Copaxone.
The QualiCop study indicated a significant improvement of cognitive function and depressive symptoms over 24 months. Patients on Copaxone experienced improved overall multiple sclerosis functional composite (MSFC) scores; the MSFC measures leg function/ambulation, arm/hand function and cognitive function. The study followed 734 patients who were either treatment naive or previously-treated with other approved injectable and infused disease modifying therapies for relapsing-remitting multiple sclerosis. In both studies, patients treated with Copaxone also demonstrated stable EDSS (no disease progression) during the study periods.
The Coptimize study is an international, non-interventional, longitudinal study, recruiting relapsing-remitting multiple sclerosis (RRMS) patients switching to Copaxone from other injectable and infused disease modifying therapies approved for RRMS within three to six months of screening.
Release Date: April 14, 2011
Source: Teva Pharmaceutical
Filed Under: Drug Discovery